Skip to main content

Drug Delivery and Targeting

The Drug Delivery and Targeting (DDT) group, led by Dr. Ibane Abasolo, works on the development, testing and validation of new therapeutic strategies based on nanotechnology, with which to provide solutions to unmeet clinical needs in the field of oncology and some rare diseases. In short, it is about generating new scientific/biomedical knowledge that can be efficiently transferred to clinical practice.

DDT works on three priority lines:

  • Study of the molecular and cellular bases of the intercommunication between tumor cells and their environment.
  • Design, synthesis and characterization of synthetic nanotechnological systems, especially polymeric micelles and hydrogels with which to improve the therapeutic window of drugs, nucleic acids and advanced therapies.
  • Use of biological nano-systems, in particular, extracellular vesicles as a vehicle for therapeutic proteins and biomolecules, especially in lysosomal storage diseases.

Within DDT we include the FVPR / U20 service platform, integrated into the ICTS-Nanbiosis and certified with ISO9001: 2015.

Team

Sandra Mancilla Zamora

Sandra Mancilla Zamora

Research technician
Drug Delivery and Targeting
Read more
Simon Schwartz Navarro

Simon Schwartz Navarro

Senior researcher
Drug Delivery and Targeting
Read more
Guillem Pintos Morell

Guillem Pintos Morell

Postdoctoral researcher
Drug Delivery and Targeting
Read more
Diego Baranda Martínez-Abasca

Diego Baranda Martínez-Abasca

Predoctoral researcher
Drug Delivery and Targeting
Read more
Marc Miquel Moltó Abad

Marc Miquel Moltó Abad

Predoctoral researcher
Drug Delivery and Targeting
Read more
Ana Maria Ogando Rodriguez

Ana Maria Ogando Rodriguez

Research technician
Drug Delivery and Targeting
Read more
Sandra Mancilla Zamora

Sandra Mancilla Zamora

Research technician
Drug Delivery and Targeting
Read more
Simon Schwartz Navarro

Simon Schwartz Navarro

Senior researcher
Drug Delivery and Targeting
Read more
Guillem Pintos Morell

Guillem Pintos Morell

Postdoctoral researcher
Drug Delivery and Targeting
Read more
Diego Baranda Martínez-Abasca

Diego Baranda Martínez-Abasca

Predoctoral researcher
Drug Delivery and Targeting
Read more
Marc Miquel Moltó Abad

Marc Miquel Moltó Abad

Predoctoral researcher
Drug Delivery and Targeting
Read more
Ana Maria Ogando Rodriguez

Ana Maria Ogando Rodriguez

Research technician
Drug Delivery and Targeting
Read more

Research lines

Applied Nanomedicine: new drug delivery and targeting strategies for biomedical applications

IP: Simó Schwartz Navarro We focus into new targeting strategies to ensure a specific delivery of therapeutic compounds into the most appropriate target cell to improve treatment response and achieve lower toxicity and higher therapeutic activities in several human diseases, with particular interest in delivery of chemotherapeutic drugs to cancer cells and enzyme replacement therapies for rare diseases. In addition, alternative targeting strategies are being designed to improve imaging-based diagnostics by using new cell-targeted nanoconjugates. Some of the projects explained bellow are developed in collaboration with other groups at CIBER-BBN (Centro de Investigaciones en Red en Biomateriales, Bioingenería y Nanomedicina, Instituto de Salud Carlos III) or within specific European consortiums. i) Enzyme replacement therapy for storage diseases: new therapeutic strategies Fabry disease is an X-linked recessive disorder caused by a deficiency of lysosomal hydrolase ?-galactosidase A (GLA). This enzymatic defect causes the progressive cellular accumulation of neutral glycosphingolipids, giving rise to a multisystemic clinical symptomatology. Current enzyme replacement therapy (ERT) has a limited treatment efficacy in patients with advanced stages of the disease. The objective of this research line is to improve the ERT by using new therapeutic compounds (nanoparticles or specifically designed proteins) of GLA targeted to the endothelial cells, one of the main cell type affected by GLA substrate accumulation. In addition, we also collaborate in a project focused on the validation of new integrated, multi-host approaches for the improved microbial production of high quality GLA enzymes for industrial purposes (IMAPPROT). ii) NANOSTEM: Targeting Combined Therapy to Cancer Stem Cells In many solid tumors, resistance to therapy and metastatic disease seem to be sustained by the presence within the tumors of the cancer stem cells (CSC) capable of regenerating a tumor after chemotherapy and/or radiation treatment. In breast cancer, these cells correspond to a small fraction of cells within the tumor that express stem cell markers (CD44+/CD24-/low/lin-) which provides a useful target to the delivery of therapeutic agents to CSC. In this network project some of the partners will focus into the design of specific vehicles for the simultaneous deliver of chemotherapeutic drugs and/or shRNAs with known antitumor activity to breast CSC. To this end, different types of nanoparticles will be directed to the CSC compartment by using the CD44 receptor as a target. Such systems will allow specific CSC-targeting, and together with the enhanced retention an permeability effect (EPR) will improve accumulation of drugs into the tumor area and should yield better therapeutic response. At CIBBIM-Nanomedicine, therapeutic activity, nanoparticle internalization and toxicology of these nanoparticulated systems will be addressed by using adequate in vitro and in vivo CSC models. iii) ONCONANOTARGET: Advancing the field of drug delivery - combined targeted treatments against human breast cancer and human leukemia The idea in the ONCONANOTARGET Network is to selectively abrogate tumour-protective functions aiming at either improving sensitivity of tumour cells to chemotherapy or finding synergistic combinations that may improve the clinical outcome for the treatment of breast cancer or leukaemia patients. Therefore, the main objectives of this project are: (i) To design and characterise ligand-targeted nanosystems for nucleic acid (siRNA) and drug delivery; (ii) To compare, in vitro, the gene-silencing efficiency of the developed targeted lipid-based or polymeric-based nanosized systems containing nucleic acids against Bcl-2 oncogene in breast cancer leukaemia and cells; (iii) To evaluate the cytotoxic activity of individual treatments with either gene silencing with targeted system previously selected or targeted polymer-anticancer drug conjugate as compared to combined treatments (targeted gene silencing combined with targeted polymer-anticancer drug conjugates) against leukaemia and breast tumour cells; and (iv) Therapeutic evaluation of the treatment modality previously selected in an animal model of human breast cancer. In this project, in vivo proof of concept will be limited to breast cancer. iv) Treatment of advanced colorectal cancer by novel drug delivery systems, sensitive to metalloproteinases Current chemotherapeutic treatment for colorectal cancer implies the use of high doses of cytotoxic medicaments, specifically adjuvant combinations of 5-fluorouracil and Irinotecan, which bring many adverse effects to the affected patient. This project proposes a program centred on the development of new nanomedicines, based on polymers of multifunctional character that brought together different chemotherapeutic agents, allowing a combined double or triple therapy using much lower systemic doses and significantly reducing undesirable side-effects. In this case, we will focus on increasing these advantages with the utilization of synthetic peptides sensitive to degradation by matrix metalloproteases (MMP), which will bind the polymeric nanocarrier to the chemotherapeutic drug. The activity of MMPs will favour the liberation of the drug and its activity in MMP rich environments, so to say primary tumors and metastatic sites. The project includes the processes of synthesis, chemical characterization and optimization of the nanomedicines, as well as their in vitro and in vivo validation.

IP: -

Applied Nanomedicine: new drug delivery and targeting strategies for biomedical applications

IP: Simó Schwartz Navarro We focus into new targeting strategies to ensure a specific delivery of therapeutic compounds into the most appropriate target cell to improve treatment response and achieve lower toxicity and higher therapeutic activities in several human diseases, with particular interest in delivery of chemotherapeutic drugs to cancer cells and enzyme replacement therapies for rare diseases. In addition, alternative targeting strategies are being designed to improve imaging-based diagnostics by using new cell-targeted nanoconjugates. Some of the projects explained bellow are developed in collaboration with other groups at CIBER-BBN (Centro de Investigaciones en Red en Biomateriales, Bioingenería y Nanomedicina, Instituto de Salud Carlos III) or within specific European consortiums. i) Enzyme replacement therapy for storage diseases: new therapeutic strategies Fabry disease is an X-linked recessive disorder caused by a deficiency of lysosomal hydrolase ?-galactosidase A (GLA). This enzymatic defect causes the progressive cellular accumulation of neutral glycosphingolipids, giving rise to a multisystemic clinical symptomatology. Current enzyme replacement therapy (ERT) has a limited treatment efficacy in patients with advanced stages of the disease. The objective of this research line is to improve the ERT by using new therapeutic compounds (nanoparticles or specifically designed proteins) of GLA targeted to the endothelial cells, one of the main cell type affected by GLA substrate accumulation. In addition, we also collaborate in a project focused on the validation of new integrated, multi-host approaches for the improved microbial production of high quality GLA enzymes for industrial purposes (IMAPPROT). ii) NANOSTEM: Targeting Combined Therapy to Cancer Stem Cells In many solid tumors, resistance to therapy and metastatic disease seem to be sustained by the presence within the tumors of the cancer stem cells (CSC) capable of regenerating a tumor after chemotherapy and/or radiation treatment. In breast cancer, these cells correspond to a small fraction of cells within the tumor that express stem cell markers (CD44+/CD24-/low/lin-) which provides a useful target to the delivery of therapeutic agents to CSC. In this network project some of the partners will focus into the design of specific vehicles for the simultaneous deliver of chemotherapeutic drugs and/or shRNAs with known antitumor activity to breast CSC. To this end, different types of nanoparticles will be directed to the CSC compartment by using the CD44 receptor as a target. Such systems will allow specific CSC-targeting, and together with the enhanced retention an permeability effect (EPR) will improve accumulation of drugs into the tumor area and should yield better therapeutic response. At CIBBIM-Nanomedicine, therapeutic activity, nanoparticle internalization and toxicology of these nanoparticulated systems will be addressed by using adequate in vitro and in vivo CSC models. iii) ONCONANOTARGET: Advancing the field of drug delivery - combined targeted treatments against human breast cancer and human leukemia The idea in the ONCONANOTARGET Network is to selectively abrogate tumour-protective functions aiming at either improving sensitivity of tumour cells to chemotherapy or finding synergistic combinations that may improve the clinical outcome for the treatment of breast cancer or leukaemia patients. Therefore, the main objectives of this project are: (i) To design and characterise ligand-targeted nanosystems for nucleic acid (siRNA) and drug delivery; (ii) To compare, in vitro, the gene-silencing efficiency of the developed targeted lipid-based or polymeric-based nanosized systems containing nucleic acids against Bcl-2 oncogene in breast cancer leukaemia and cells; (iii) To evaluate the cytotoxic activity of individual treatments with either gene silencing with targeted system previously selected or targeted polymer-anticancer drug conjugate as compared to combined treatments (targeted gene silencing combined with targeted polymer-anticancer drug conjugates) against leukaemia and breast tumour cells; and (iv) Therapeutic evaluation of the treatment modality previously selected in an animal model of human breast cancer. In this project, in vivo proof of concept will be limited to breast cancer. iv) Treatment of advanced colorectal cancer by novel drug delivery systems, sensitive to metalloproteinases Current chemotherapeutic treatment for colorectal cancer implies the use of high doses of cytotoxic medicaments, specifically adjuvant combinations of 5-fluorouracil and Irinotecan, which bring many adverse effects to the affected patient. This project proposes a program centred on the development of new nanomedicines, based on polymers of multifunctional character that brought together different chemotherapeutic agents, allowing a combined double or triple therapy using much lower systemic doses and significantly reducing undesirable side-effects. In this case, we will focus on increasing these advantages with the utilization of synthetic peptides sensitive to degradation by matrix metalloproteases (MMP), which will bind the polymeric nanocarrier to the chemotherapeutic drug. The activity of MMPs will favour the liberation of the drug and its activity in MMP rich environments, so to say primary tumors and metastatic sites. The project includes the processes of synthesis, chemical characterization and optimization of the nanomedicines, as well as their in vitro and in vivo validation.

IP: -

Development of nanotechnology systems for the treatment and diagnosis of cancer

The identification of biomarkers in cancer stem cells allows us to develop targeted nanosystems, either because we use targeting moieties (antibodies or peptide sequences on the surface of the nanoparticles) or because we act directly on essential molecules in the maintenance of the CSC population (Pesarrodona et al., Biofabrication 2016). Therapeutic systems consist of biodegradable polymers that covalently anchor the drug or incorporate it into micellar structures (Gener et al., Nanomedicine, 2015, Andrade et al., Nanomedicine, 2015, Rocas et al., J Mater Chem, 2015). The use of these systems increases the efficiency and reduces the toxicity of conventional treatments (Schwartz, Nanomedicine 2017). In parallel, we also work on the combined use of chemotherapeutic treatments with alternative treatments such as hyperthermia using magnetic nanoparticles (Nocanther project). In the DDT group, nanotechnological systems are not only used for therapy but also for imaging, initially with non-directional nanosystems that accumulate in tumor areas due to the defect of the tumor vasculature (Candiota et al., J Nanobiotechnology, 2014 ; Bomatí-Miguel et al., J Nanoparticle Res), but also by means of directionalised systems. Projects: Alox5, Targets4Cancer, DiamESTar, NoCanTher and FIS

IP: Simon Schwartz Navarro, Ibane Abasolo Olaortua

Diagnostic Nanotools for for fast assay and biosensor development (DINA)

PI: Eva Baldrich Rubio One of the greatest challenges in global healthcare is the lack of adequate diagnostic tools for early disease detection and adequate treatment monitoring. Accordingly, the development of low-cost, rapid, sensitive and robust bioassays and biosensors has become a priority for the healthcare sector and the research community. It is for this reason that the recent advances in rapidly evolving fields, such as Nanotechnology and Biosensor development, have raised great expectations and bitter controversies. DINA is brought to live in 2014 with a main goal: the exploitation of nanostructures, nanomaterials and nanocomponents as transducers, biofunctionalization platforms and signal amplifiers for fast assay and biosensor development. But always bearing in mind a final and clear objective: the production and/or improvement of realistic diagnostic tools that could be effectively used at a diagnostics laboratory. i) Electrochemical Biosensors as diagnostic tools. By definition, a biosensor is a bioanalytical device that incorporates a molecular recognition element (bioreceptor) associated to, or integrated with, a physicochemical transducer. According to this, a biosensor is formed by three components: a bioreceptor able to capture specifically the target of interest, a signal transducer able to convert target binding into a measurable electrical signal, and a signal processor that quantifies, analyzes and displays the results. In this way, analyte biocapture can be directly translated into a measurable signal. To date, numerous biosensors have been developed using a wide variety of biorecognition elements (ranging from “classical” bioreceptors such as antibodies, nucleic acid probes, antigens or enzymes, to novel alternatives like aptamers, biomimetic polymers or phage displayed peptides) and types of transducers (principally clustered into optical, electrochemical and micromechanical). ii) Nanocomponents and Nanostructured Materials in Fast Assay and Biosensor Development. Nanotechnology is a rapidly emerging field that is having an enormous impact on assay and biosensor development and, by extension, in their application to diagnostics. Nanomaterials can display almost unlimited combinations of composition, size, dimensions and shape, which can be tailored and coupled to bioreceptors in order to produce nanoprobes with desired properties. Since nanostructures are characterized by high surface to volume ratios, they have been extensively used as multi-label carriers for signal amplification. In opposition to detection using bioreceptors conjugated to a single label unit, multi-label nanoparticles have been claimed to provide higher and faster responses, contributing to improved bioassay/biosensor detection limits by up to three orders of magnitude. Alternatively, a variety of nanomaterials, such as fullerene derivatives, gold nanoparticles, rare earth nanoparticles and ferromagnetic nanoparticles, have been explored as artificial enzymes or enzyme mimics (nanozymes) thanks to their intrinsic non-enzymatic catalytic activity for a variety of molecular substrates. Used as labels in bioassay/biosensor development, nanozymes appear to be more stable and cheaper alternatives than natural enzymes. A particular example is nanoparticle-induced metal deposition. For instance gold nanoparticles can selectively reduce silver and gold salts to silver or gold, respectively, in the presence of a reducing agent. This results in significantly increased size which affects directly electrode transduction.

IP: -

Projects

HONING EXTRACELLULAR VESICLES TO INHIBIT KRAS IN METASTATIC PANCREATIC CANCER

IP: Ibane Abasolo Olaortua
Collaborators: Diego Baranda Martínez-Abasca, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 50649.27
Reference: VHIR/BEQUESPREDOC/2020/BARANDA
Duration: 01/04/2021 - 31/03/2024

Encara per definir

IP: Ibane Abasolo Olaortua
Collaborators: Diego Baranda Martínez-Abasca, Miriam Izquierdo Sans
Funding agency: Ministerio de Educación, Cultura y Deporte
Funding: 59223.42
Reference: FPU20/04210
Duration: 01/12/2021 - 31/03/2025

Design of Nanoparticles for Blood-Brain-Barrier Crossing and Glioblastoma Multiforme Cancer Stem Cells Targeting (NanoGlio)

IP: Ibane Abasolo Olaortua
Collaborators: Fernanda Raquel Da Silva Andrade, Miriam Izquierdo Sans
Funding agency: Asociación Española Contra el Cáncer
Funding: 100000
Reference: INVES211530DASI
Duration: 01/09/2021 - 31/08/2023

Mejora del tratamiento de las enfermedades de depósito lisosomal mediante vehículos nanométricos optimizados

IP: Ibane Abasolo Olaortua
Collaborators: Marc Miquel Moltó Abad, Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 90306.55
Reference: SLT017/20/000181
Duration: 05/07/2021 - 31/12/2024

Desenvolupament d¿assaigs preclínics de nanosistemes per estudis clínics amb aplicació en càncer ductal pancreàtic.

IP: Simon Schwartz Navarro
Collaborators: Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 67280.97
Reference: SLT006/17/00270
Duration: 01/03/2018 - 14/05/2021

HONING EXTRACELLULAR VESICLES TO INHIBIT KRAS IN METASTATIC PANCREATIC CANCER

IP: Ibane Abasolo Olaortua
Collaborators: Diego Baranda Martínez-Abasca, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 50649.27
Reference: VHIR/BEQUESPREDOC/2020/BARANDA
Duration: 01/04/2021 - 31/03/2024

Encara per definir

IP: Ibane Abasolo Olaortua
Collaborators: Diego Baranda Martínez-Abasca, Miriam Izquierdo Sans
Funding agency: Ministerio de Educación, Cultura y Deporte
Funding: 59223.42
Reference: FPU20/04210
Duration: 01/12/2021 - 31/03/2025

Design of Nanoparticles for Blood-Brain-Barrier Crossing and Glioblastoma Multiforme Cancer Stem Cells Targeting (NanoGlio)

IP: Ibane Abasolo Olaortua
Collaborators: Fernanda Raquel Da Silva Andrade, Miriam Izquierdo Sans
Funding agency: Asociación Española Contra el Cáncer
Funding: 100000
Reference: INVES211530DASI
Duration: 01/09/2021 - 31/08/2023

Sistemas de liberación farmacológica dirigidos contra células madre tumorales- prueba de concepto

IP: Simon Schwartz Navarro
Collaborators: Joaquin Seras Franzoso, Miriam Izquierdo Sans
Funding agency: Asociación Española Contra el Cáncer
Funding: 135000
Reference: 2014/AECC-AIO/SERAS
Duration: 01/02/2015 - 31/01/2020

Desenvolupament d¿assaigs preclínics de nanosistemes per estudis clínics amb aplicació en càncer ductal pancreàtic.

IP: Simon Schwartz Navarro
Collaborators: Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 67280.97
Reference: SLT006/17/00270
Duration: 01/03/2018 - 14/05/2021

(Nano) sistemes amb direccionament actiu per sensibilitzar cèl¿lules mare de càncer de còlon com a tractament antitumoral

IP: Ibane Abasolo Olaortua
Collaborators: Francesc Martínez Trucharte, Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 67280.97
Reference: SLT006/17/00259
Duration: 01/03/2018 - 31/12/2020

NoCanTher: Nanomedicine Upscaling for Early Clinical Phases of Multimodal Cancer Therapy

IP: Simon Schwartz Navarro
Collaborators: Ibane Abasolo Olaortua, Joaquin Seras Franzoso, Tamara Del Rio Higueras, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Olga Sánchez- Maroto Carrizo, Angelica Valderrama Rodríguez
Funding agency: EUROPEAN COMMISSION
Funding: 630633.55
Reference: NOCANTHER_H2020NMP2015
Duration: 01/04/2016 - 30/09/2021

Sistemas de liberación farmacológica dirigidos contra células madre tumorales- prueba de concepto

IP: Simon Schwartz Navarro
Collaborators: Joaquin Seras Franzoso, Miriam Izquierdo Sans
Funding agency: Asociación Española Contra el Cáncer
Funding: 135000
Reference: 2014/AECC-AIO/SERAS
Duration: 01/02/2015 - 31/01/2020

Desenvolupament d¿assaigs preclínics de nanosistemes per estudis clínics amb aplicació en càncer ductal pancreàtic.

IP: Simon Schwartz Navarro
Collaborators: Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 67280.97
Reference: SLT006/17/00270
Duration: 01/03/2018 - 14/05/2021

(Nano) sistemes amb direccionament actiu per sensibilitzar cèl¿lules mare de càncer de còlon com a tractament antitumoral

IP: Ibane Abasolo Olaortua
Collaborators: Francesc Martínez Trucharte, Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 67280.97
Reference: SLT006/17/00259
Duration: 01/03/2018 - 31/12/2020

Targeted delivery of therapeutic siRNA to Ewing sarcoma junction oncogene by traceable diamond nanocrystal - antibody conjugate DiamESTar

IP: Ibane Abasolo Olaortua
Collaborators: Targeted delivery of therapeutic siRNA to Ewing sarcoma junction oncogene by traceable diamond nanocrystal - antibody conjugate
Funding agency: Instituto de Salud Carlos III
Funding: 75000.64
Reference: AC14/00032
Duration: 01/01/2015 - 30/06/2019

Sistemas de liberación farmacológica dirigidos contra células madre tumorales- prueba de concepto

IP: Simon Schwartz Navarro
Collaborators: Joaquin Seras Franzoso, Miriam Izquierdo Sans
Funding agency: Asociación Española Contra el Cáncer
Funding: 135000
Reference: 2014/AECC-AIO/SERAS
Duration: 01/02/2015 - 31/01/2020

Desenvolupament d¿assaigs preclínics de nanosistemes per estudis clínics amb aplicació en càncer ductal pancreàtic.

IP: Simon Schwartz Navarro
Collaborators: Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 67280.97
Reference: SLT006/17/00270
Duration: 01/03/2018 - 14/05/2021

(Nano) sistemes amb direccionament actiu per sensibilitzar cèl¿lules mare de càncer de còlon com a tractament antitumoral

IP: Ibane Abasolo Olaortua
Collaborators: Francesc Martínez Trucharte, Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 67280.97
Reference: SLT006/17/00259
Duration: 01/03/2018 - 31/12/2020

Targeted delivery of therapeutic siRNA to Ewing sarcoma junction oncogene by traceable diamond nanocrystal - antibody conjugate DiamESTar

IP: Ibane Abasolo Olaortua
Collaborators: Targeted delivery of therapeutic siRNA to Ewing sarcoma junction oncogene by traceable diamond nanocrystal - antibody conjugate
Funding agency: Instituto de Salud Carlos III
Funding: 75000.64
Reference: AC14/00032
Duration: 01/01/2015 - 30/06/2019

Sistemas de liberación farmacológica dirigidos contra células madre tumorales- prueba de concepto

IP: Simon Schwartz Navarro
Collaborators: Joaquin Seras Franzoso, Miriam Izquierdo Sans
Funding agency: Asociación Española Contra el Cáncer
Funding: 135000
Reference: 2014/AECC-AIO/SERAS
Duration: 01/02/2015 - 31/01/2020

Infraestructura

IP: Ibane Abasolo Olaortua
Collaborators: Miriam Izquierdo Sans
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 36000
Reference: PTA2013-08431-I
Duration: 01/08/2014 - 31/07/2017

Personalized nanomedicine for triple negative breast cancer stem cells

IP: Ibane Abasolo Olaortua
Collaborators: -
Funding agency: Fundació La Marató de TV3
Funding: 174000
Reference: 337/C/2013
Duration: 18/03/2014 - 17/03/2017

Liberación dirigida de nanoconjugados de inhibidor de Alox5 contra células madre tumorales

IP: Simon Schwartz Navarro
Collaborators: Laura García Latorre, Diana Fernandes de Rafael
Funding agency: Instituto de Salud Carlos III
Funding: 171215
Reference: PI14/02079
Duration: 01/01/2015 - 31/12/2017

Sistemas de liberación farmacológica dirigidos contra células madre tumorales- prueba de concepto

IP: Simon Schwartz Navarro
Collaborators: Joaquin Seras Franzoso, Miriam Izquierdo Sans
Funding agency: Asociación Española Contra el Cáncer
Funding: 135000
Reference: 2014/AECC-AIO/SERAS
Duration: 01/02/2015 - 31/01/2020

Infraestructura

IP: Ibane Abasolo Olaortua
Collaborators: Miriam Izquierdo Sans
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 36000
Reference: PTA2013-08431-I
Duration: 01/08/2014 - 31/07/2017

Personalized nanomedicine for triple negative breast cancer stem cells

IP: Ibane Abasolo Olaortua
Collaborators: -
Funding agency: Fundació La Marató de TV3
Funding: 174000
Reference: 337/C/2013
Duration: 18/03/2014 - 17/03/2017

Liberación dirigida de nanoconjugados de inhibidor de Alox5 contra células madre tumorales

IP: Simon Schwartz Navarro
Collaborators: Laura García Latorre, Diana Fernandes de Rafael
Funding agency: Instituto de Salud Carlos III
Funding: 171215
Reference: PI14/02079
Duration: 01/01/2015 - 31/12/2017

Innovative Training Network (ITN) in Nanomedicine (NANO2EXCEL)

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 23000
Reference: EUIN2013-51211
Duration: 01/10/2013 - 30/09/2015

Sistemas de liberación farmacológica dirigidos contra células madre tumorales- prueba de concepto

IP: Simon Schwartz Navarro
Collaborators: Joaquin Seras Franzoso, Miriam Izquierdo Sans
Funding agency: Asociación Española Contra el Cáncer
Funding: 135000
Reference: 2014/AECC-AIO/SERAS
Duration: 01/02/2015 - 31/01/2020

Infraestructura

IP: Ibane Abasolo Olaortua
Collaborators: Miriam Izquierdo Sans
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 36000
Reference: PTA2013-08431-I
Duration: 01/08/2014 - 31/07/2017

Personalized nanomedicine for triple negative breast cancer stem cells

IP: Ibane Abasolo Olaortua
Collaborators: -
Funding agency: Fundació La Marató de TV3
Funding: 174000
Reference: 337/C/2013
Duration: 18/03/2014 - 17/03/2017

Innovative Training Network (ITN) in Nanomedicine (NANO2EXCEL)

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 23000
Reference: EUIN2013-51211
Duration: 01/10/2013 - 30/09/2015

Infraestructura

IP: Ibane Abasolo Olaortua
Collaborators: Miriam Izquierdo Sans
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 36000
Reference: PTA2013-08431-I
Duration: 01/08/2014 - 31/07/2017

Development of nanomedicines for enzymatic replacement therapy in Fabry disease

IP: Simon Schwartz Navarro
Collaborators: Ibane Abasolo Olaortua
Funding agency: Fundació La Marató de TV3
Funding: 214925
Reference: MARATV3/2010/101230
Duration: 03/02/2011 - 31/12/2014

Targetting Combined Therapy to Cancer Stem Cells (NANOSTEM)

IP: Simon Schwartz Navarro
Collaborators: Laura García Latorre
Funding agency: Instituto de Salud Carlos III
Funding: 145540.01
Reference: PI11/01079
Duration: 01/01/2012 - 31/12/2014

Innovative Training Network (ITN) in Nanomedicine (NANO2EXCEL)

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 23000
Reference: EUIN2013-51211
Duration: 01/10/2013 - 30/09/2015

Development of nanomedicines for enzymatic replacement therapy in Fabry disease

IP: Simon Schwartz Navarro
Collaborators: Ibane Abasolo Olaortua
Funding agency: Fundació La Marató de TV3
Funding: 214925
Reference: MARATV3/2010/101230
Duration: 03/02/2011 - 31/12/2014

POLYSFERA: Nanocápsulas poliméricas para liberación controlada y dirigida de fármacos antitumorales

IP: Ibane Abasolo Olaortua
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 505955
Reference: IPT-090000-2010-0001
Duration: 22/06/2010 - 21/06/2013

Ministerio de Ciencia

Targetting Combined Therapy to Cancer Stem Cells (NANOSTEM)

IP: Simon Schwartz Navarro
Collaborators: Laura García Latorre
Funding agency: Instituto de Salud Carlos III
Funding: 145540.01
Reference: PI11/01079
Duration: 01/01/2012 - 31/12/2014

Papel funcional de los receptores con actividad quinasa EPH y sus ligandos en el cáncer colorectal

IP: Simon Schwartz Navarro
Collaborators: Diego Arango Corro, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 153010.09
Reference: MS05/00256
Duration: 01/03/2006 - 28/02/2012

Activación de vías dependientes del oncogen BRAF en la tumorogénesis y metástasis del cáncer colorectal en modelos in vivo

IP: Simon Schwartz Navarro
Collaborators: Ibane Abasolo Olaortua, Julio Castaño Cardoso
Funding agency: Instituto de Salud Carlos III
Funding: 219252
Reference: PI080771
Duration: 01/01/2009 - 30/06/2012

Integrated approach for the improved microbial production of high quality therapeutic enzymes (IMAPPROT)

IP: Simon Schwartz Navarro
Collaborators: Diego Arango Corro, Ibane Abasolo Olaortua
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 164000
Reference: EUI2008-03741
Duration: 01/03/2009 - 30/06/2012

Ministerio de Ciencia

Development of nanomedicines for enzymatic replacement therapy in Fabry disease

IP: Simon Schwartz Navarro
Collaborators: Ibane Abasolo Olaortua
Funding agency: Fundació La Marató de TV3
Funding: 214925
Reference: MARATV3/2010/101230
Duration: 03/02/2011 - 31/12/2014

Papel funcional de los receptores con actividad quinasa EPH y sus ligandos en el cáncer colorectal

IP: Simon Schwartz Navarro
Collaborators: Diego Arango Corro, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 153010.09
Reference: MS05/00256
Duration: 01/03/2006 - 28/02/2012

Nuevos transductores para KRAS y BRAF en cáncer colorectal con inestabilidad de microsatélites esporádico y hereditario: diferencias de activación según el entorno molecular tumoral

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 54000
Reference: FI07/00002
Duration: 01/01/2008 - 31/12/2011

Validación Funcional de dianas terapéuticas y nuevas nanomedicinas en modelos in vitro e in vivo de cáncer colorectal

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13000
Reference: PRED/IR-HUVH/13/2007
Duration: 01/01/2008 - 31/12/2011

Anàlisi de l'expressió i funció del hCD 300f/CLM1 murí en cèl·lules de micròglia i identificació del lligant del mateix immunoreceptor en oligodentrocits primaris on s'estudiarà la seva possible funció

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: AGAUR
Funding: 4188
Reference: 2010 BE1 00133
Duration: 01/05/2011 - 31/07/2011

NANOSTEM-Acción complementaria

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 3000
Reference: SAF2009-08592-E
Duration: 01/11/2009 - 30/04/2010

Ministerio de Ciencia

Targetting Combined Therapy to Cancer Stem Cells (Nanoquest)

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: AGAUR
Funding: 4680.44
Reference: 2009LID2-C-20
Duration: 01/01/2010 - 20/01/2010

Papel funcional de los receptores con actividad quinasa EPH y sus ligandos en el cáncer colorectal

IP: Simon Schwartz Navarro
Collaborators: Diego Arango Corro, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 153010.09
Reference: MS05/00256
Duration: 01/03/2006 - 28/02/2012

Nuevos transductores para KRAS y BRAF en cáncer colorectal con inestabilidad de microsatélites esporádico y hereditario: diferencias de activación según el entorno molecular tumoral

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 54000
Reference: FI07/00002
Duration: 01/01/2008 - 31/12/2011

NANOSTEM-Acción complementaria

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 3000
Reference: SAF2009-08592-E
Duration: 01/11/2009 - 30/04/2010

Ministerio de Ciencia

Papel funcional de los receptores con actividad quinasa EPH y sus ligandos en el cáncer colorectal

IP: Simon Schwartz Navarro
Collaborators: Diego Arango Corro, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 153010.09
Reference: MS05/00256
Duration: 01/03/2006 - 28/02/2012

Nuevos transductores para KRAS y BRAF en cáncer colorectal con inestabilidad de microsatélites esporádico y hereditario: diferencias de activación según el entorno molecular tumoral

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 54000
Reference: FI07/00002
Duration: 01/01/2008 - 31/12/2011

Validación Funcional de dianas terapéuticas y nuevas nanomedicinas en modelos in vitro e in vivo de cáncer colorectal

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13000
Reference: PRED/IR-HUVH/13/2007
Duration: 01/01/2008 - 31/12/2011

Papel funcional de los receptores con actividad quinasa EPH y sus ligandos en el cáncer colorectal

IP: Simon Schwartz Navarro
Collaborators: Diego Arango Corro, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 153010.09
Reference: MS05/00256
Duration: 01/03/2006 - 28/02/2012

Nuevos transductores para KRAS y BRAF en cáncer colorectal con inestabilidad de microsatélites esporádico y hereditario: diferencias de activación según el entorno molecular tumoral

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 54000
Reference: FI07/00002
Duration: 01/01/2008 - 31/12/2011

Validación Funcional de dianas terapéuticas y nuevas nanomedicinas en modelos in vitro e in vivo de cáncer colorectal

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13000
Reference: PRED/IR-HUVH/13/2007
Duration: 01/01/2008 - 31/12/2011

Nuevos transductores para Kras y BRAF en cáncer colorectal con inestabilidad de microsálites esporádico y hereditario: diferencias de activación según el entorno molecular tumoral.

IP: Simon Schwartz Navarro
Collaborators: Eloy Espín Basany
Funding agency: Instituto de Salud Carlos III
Funding: 97580
Reference: PI050304
Duration: 01/01/2006 - 31/12/2008

Detección de nuevos genes de respuesta a radiaciones ionizantes y quimioterápicos mediante oligo chip-microarrays y ensayos de sensibilidad tumoral al tratamiento mediante inhibición por siRNA

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13200
Reference: PRED/IR-HUVH/17/2003
Duration: 01/01/2004 - 31/12/2007

Vías moleculares de respuesta genotóxica al tratamiento quimio- y radioterápico tumoral. Detección de nuevos implicados.

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 1393.2
Reference: BF03/00595
Duration: 01/01/2004 - 30/11/2007

Papel funcional de los receptores con actividad quinasa EPH y sus ligandos en el cáncer colorectal

IP: Simon Schwartz Navarro
Collaborators: Diego Arango Corro, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 153010.09
Reference: MS05/00256
Duration: 01/03/2006 - 28/02/2012

Nuevos transductores para Kras y BRAF en cáncer colorectal con inestabilidad de microsálites esporádico y hereditario: diferencias de activación según el entorno molecular tumoral.

IP: Simon Schwartz Navarro
Collaborators: Eloy Espín Basany
Funding agency: Instituto de Salud Carlos III
Funding: 97580
Reference: PI050304
Duration: 01/01/2006 - 31/12/2008

Detección de nuevos genes de respuesta a radiaciones ionizantes y quimioterápicos mediante oligo chip-microarrays y ensayos de sensibilidad tumoral al tratamiento mediante inhibición por siRNA

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13200
Reference: PRED/IR-HUVH/17/2003
Duration: 01/01/2004 - 31/12/2007

Vías moleculares de respuesta genotóxica al tratamiento quimio- y radioterápico tumoral. Detección de nuevos implicados.

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 1393.2
Reference: BF03/00595
Duration: 01/01/2004 - 30/11/2007

Papel funcional de los receptores con actividad quinasa EPH y sus ligandos en el cáncer colorectal

IP: Simon Schwartz Navarro
Collaborators: Diego Arango Corro, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 153010.09
Reference: MS05/00256
Duration: 01/03/2006 - 28/02/2012

Nuevos transductores para Kras y BRAF en cáncer colorectal con inestabilidad de microsálites esporádico y hereditario: diferencias de activación según el entorno molecular tumoral.

IP: Simon Schwartz Navarro
Collaborators: Eloy Espín Basany
Funding agency: Instituto de Salud Carlos III
Funding: 97580
Reference: PI050304
Duration: 01/01/2006 - 31/12/2008

Detección de nuevos genes de respuesta a radiaciones ionizantes y quimioterápicos mediante oligo chip-microarrays y ensayos de sensibilidad tumoral al tratamiento mediante inhibición por siRNA

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13200
Reference: PRED/IR-HUVH/17/2003
Duration: 01/01/2004 - 31/12/2007

Vías moleculares de respuesta genotóxica al tratamiento quimio- y radioterápico tumoral. Detección de nuevos implicados.

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 1393.2
Reference: BF03/00595
Duration: 01/01/2004 - 30/11/2007

Mutaciones somáticas mitocondriales en tumores gástricos y su asociación con el pronóstico tumoral. Dinámica mutacional de heteroplasmias en la línea colorectal inestable DLD-1.

IP: Simon Schwartz Navarro
Collaborators: José Manuel Pena Ezquerra, Jordi Giralt López de Sagred, Manuel Armengol Carrasco, Eloy Espín Basany
Funding agency: Instituto de Salud Carlos III
Funding: 112125
Reference: PI020295
Duration: 06/11/2002 - 06/11/2005

Detección de nuevos genes de respuesta a radiaciones ionizantes y quimioterápicos mediante oligo chip-microarrays y ensayos de sensibilidad tumoral al tratamiento mediante inhibición por siRNA

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13200
Reference: PRED/IR-HUVH/17/2003
Duration: 01/01/2004 - 31/12/2007

Vías moleculares de respuesta genotóxica al tratamiento quimio- y radioterápico tumoral. Detección de nuevos implicados.

IP: Simon Schwartz Navarro
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 1393.2
Reference: BF03/00595
Duration: 01/01/2004 - 30/11/2007

Mutaciones somáticas mitocondriales en tumores gástricos y su asociación con el pronóstico tumoral. Dinámica mutacional de heteroplasmias en la línea colorectal inestable DLD-1.

IP: Simon Schwartz Navarro
Collaborators: José Manuel Pena Ezquerra, Jordi Giralt López de Sagred, Manuel Armengol Carrasco, Eloy Espín Basany
Funding agency: Instituto de Salud Carlos III
Funding: 112125
Reference: PI020295
Duration: 06/11/2002 - 06/11/2005

Aplicabilidad clinica del analisis de la inestabilidad de microsatelites en el cancer colorectal. diagnostico molecular del cancer colorectal hereditario no polipoide (hnpcc) y protocolos alternativos de diagnostico.

IP: Simon Schwartz Navarro
Collaborators: José Manuel Pena Ezquerra, Aplicabilidad clinica del analisis de la inestabilidad de microsatelites en el cancer colorectal. diagnostico molecular del canc, Jordi Giralt López de Sagred, Manuel Armengol Carrasco, Eloy Espín Basany
Funding agency: Instituto de Salud Carlos III
Funding: 95861.43
Reference: 01/1350
Duration: 17/07/2001 - 31/12/2003

Mutaciones somáticas mitocondriales en tumores gástricos y su asociación con el pronóstico tumoral. Dinámica mutacional de heteroplasmias en la línea colorectal inestable DLD-1.

IP: Simon Schwartz Navarro
Collaborators: José Manuel Pena Ezquerra, Jordi Giralt López de Sagred, Manuel Armengol Carrasco, Eloy Espín Basany
Funding agency: Instituto de Salud Carlos III
Funding: 112125
Reference: PI020295
Duration: 06/11/2002 - 06/11/2005

Aplicabilidad clinica del analisis de la inestabilidad de microsatelites en el cancer colorectal. diagnostico molecular del cancer colorectal hereditario no polipoide (hnpcc) y protocolos alternativos de diagnostico.

IP: Simon Schwartz Navarro
Collaborators: José Manuel Pena Ezquerra, Aplicabilidad clinica del analisis de la inestabilidad de microsatelites en el cancer colorectal. diagnostico molecular del canc, Jordi Giralt López de Sagred, Manuel Armengol Carrasco, Eloy Espín Basany
Funding agency: Instituto de Salud Carlos III
Funding: 95861.43
Reference: 01/1350
Duration: 17/07/2001 - 31/12/2003

Mutaciones somáticas mitocondriales en tumores gástricos y su asociación con el pronóstico tumoral. Dinámica mutacional de heteroplasmias en la línea colorectal inestable DLD-1.

IP: Simon Schwartz Navarro
Collaborators: José Manuel Pena Ezquerra, Jordi Giralt López de Sagred, Manuel Armengol Carrasco, Eloy Espín Basany
Funding agency: Instituto de Salud Carlos III
Funding: 112125
Reference: PI020295
Duration: 06/11/2002 - 06/11/2005

Aplicabilidad clinica del analisis de la inestabilidad de microsatelites en el cancer colorectal. diagnostico molecular del cancer colorectal hereditario no polipoide (hnpcc) y protocolos alternativos de diagnostico.

IP: Simon Schwartz Navarro
Collaborators: José Manuel Pena Ezquerra, Aplicabilidad clinica del analisis de la inestabilidad de microsatelites en el cancer colorectal. diagnostico molecular del canc, Jordi Giralt López de Sagred, Manuel Armengol Carrasco, Eloy Espín Basany
Funding agency: Instituto de Salud Carlos III
Funding: 95861.43
Reference: 01/1350
Duration: 17/07/2001 - 31/12/2003

Publications

Perspectives toward the development of advanced materials based on bacterial polysaccharides.

PMID: 35770400
Journal: CURRENT MEDICINAL CHEMISTRY
Year: 2022
Reference: Curr Med Chem. 2022 Jun 29. pii: CMC-EPUB-124889. doi: 10.2174/0929867329666220629152008.
Impact factor: 4.53
Publication type: Paper in international publication
Authors: Rafael, Diana; Marican, Adolfo; Duran-Lara, Esteban F; Vijayakumar, Sekar et al.
DOI: 10.2174/0929867329666220629152008

Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry.

PMID: 35725623
Journal: Orphanet Journal of Rare Diseases
Year: 2022
Reference: Orphanet J Rare Dis. 2022 Jun 20;17(1):238. doi: 10.1186/s13023-022-02392-9.
Impact factor: 4.123
Publication type: Review in international publication
Authors: Beck, Michael, Ramaswami, Uma, Hernberg-Stahl, Elizabeth, Hughes, Derralynn A, Kampmann, Christoph, Mehta, Atul B, Nicholls, Kathleen, Niu, Dau-Ming, Pintos-Morell, Guillem, Reisin, Ricardo et al.
DOI: 10.1186/s13023-022-02392-9

In Vivo ANTI-TUMOR and Metastatic Efficacy of A polyacetal-Based Paclitaxel Conjugate for Prostate Cancer Therapy.

PMID: 34706167
Journal: Advanced Healthcare Materials
Year: 2022
Reference: Adv Healthc Mater. 2022 Apr;11(7):e2101544. doi: 10.1002/adhm.202101544. Epub 2021 Nov 10.
Impact factor: 9.933
Publication type: Paper in international publication
Authors: Vicent, Maria J, Abasolo, Ibane, Fernandez, Yolanda, Movellan, Julie, Foradada, Laia, Gimenez, Vanessa, Garcia-Aranda, Natalia, Mancilla, Sandra, Arminan, Ana, Borgos, Sven Even et al.
DOI: 10.1002/adhm.202101544

Colorectal cancer inhibition by BET inhibitor JQ1 is MYC-independent and not improved by nanoencapsulation.

PMID: 34998911
Journal: EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Year: 2022
Reference: Eur J Pharm Biopharm. 2022 Feb;171:39-49. doi: 10.1016/j.ejpb.2021.10.017. Epub 2022 Jan 5.
Impact factor: 5.571
Publication type: Paper in international publication
Authors: Fourniols, Thibaut, Maggio, Valentina, Rafael, Diana, Colaco, Ariana, Garcia Vidal, Elia, Lopes, Alessandra, Schwartz, Simo, Martinez-Barriocanal, Agueda, Preat, Veronique, Arango, Diego et al.
DOI: 10.1016/j.ejpb.2021.10.017

Characterization of RAN Translation and Antisense Transcription in Primary Cell Cultures of Patients with Myotonic Dystrophy Type 1.

PMID: 34884222
Journal: Journal of Clinical Medicine
Year: 2021
Reference: J Clin Med. 2021 Nov 25;10(23). pii: jcm10235520. doi: 10.3390/jcm10235520.
Impact factor: 4.242
Publication type: Paper in international publication
Authors: Pintos-Morell, Guillem, Coll-Canti, Jaume, Ramos-Fransi, Alba, Martinez-Pineiro, Alicia, Suelves, Monica, Nogales-Gadea, Gisela, Gomez-Escribano, Ana Pilar, Vazquez-Manrique, Rafael P, Arbex, Andrea, Koehorst, Emma et al.
DOI: 10.3390/jcm10235520

Development of "on-demand" thermo-responsive hydrogels for anti-cancer drugs sustained release: Rational design, in silico prediction and in vitro validation in colon cancer models.

PMID: 34857269
Journal: Materials Science & Engineering C-Materials for Biological Applications
Year: 2021
Reference: Mater Sci Eng C Mater Biol Appl. 2021 Dec;131:112483. doi: 10.1016/j.msec.2021.112483. Epub 2021 Oct 13.
Impact factor: 7.328
Publication type: Paper in international publication
Authors: Carreno, Gustavo, Pereira, Alfredo, Avila-Salas, Fabian, Marican, Adolfo, Andrade, Fernanda, Roca-Melendres, Maria Merce, Valdes, Oscar, Vijayakumar, Sekar, Schwartz, Simo Jr, Abasolo, Ibane et al.
DOI: 10.1016/j.msec.2021.112483

Clinical features and health-related quality of life in adult patients with mucopolysaccharidosis IVA: the Spanish experience.

PMID: 34732228
Journal: Orphanet Journal of Rare Diseases
Year: 2021
Reference: Orphanet J Rare Dis. 2021 Nov 3;16(1):464. doi: 10.1186/s13023-021-02074-y.
Impact factor: 4.123
Publication type: Paper in international publication
Authors: Quijada-Fraile, Pilar, Arranz Canales, Elena, Martin-Hernandez, Elena, Ballesta-Martinez, Maria Juliana, Guillen-Navarro, Encarna, Pintos-Morell, Guillem, Molto-Abad, Marc, Moreno-Martinez, David, Garcia Morillo, Salvador, Blasco-Alonso, Javier et al.
DOI: 10.1186/s13023-021-02074-y

Thermo-Responsive Hydrogels for Cancer Local Therapy: Challenges and State-of-Art.

PMID: 34332061
Journal: INTERNATIONAL JOURNAL OF PHARMACEUTICS
Year: 2021
Reference: Int J Pharm. 2021 Sep 5;606:120954. doi: 10.1016/j.ijpharm.2021.120954. Epub 2021 Jul 28.
Impact factor: 5.875
Publication type: Review in international publication
Authors: Rafael, Diana, Merce Roca Melendres, Maria, Andrade, Fernanda, Montero, Sara, Martinez-Trucharte, Francesc, Martinez-Trucharte, Francesc, Vilar-Hernandez, Mireia, Francisco Duran-Lara, Esteban, Schwartz, Simo Jr, Abasolo, Ibane et al.
DOI: 10.1016/j.ijpharm.2021.120954

The potential of nanomedicine to alter cancer stem cell dynamics: the impact of extracellular vesicles.

PMID: 33191837
Journal: Nanomedicine
Year: 2020
Reference: Nanomedicine (Lond). 2020 Dec;15(28):2785-2800. doi: 10.2217/nnm-2020-0099. Epub 2020 Nov 16.
Impact factor: 4.3
Publication type: Paper in international publication
Authors: Gener, Petra, Callejo, Patricia Gonzalez, Seras-Franzoso, Joaquin, Andrade, Fernanda, Rafael, Diana, Abasolo, Ibane, Schwartz, Simo Jr et al.
DOI: 10.2217/nnm-2020-0099

Preliminary Findings on CTG Expansion Determination in Different Tissues from Patients with Myotonic Dystrophy Type 1.

PMID: 33171734
Journal: Genes
Year: 2020
Reference: Genes (Basel). 2020 Nov 7;11(11). pii: genes11111321. doi: 10.3390/genes11111321.
Impact factor: 3.759
Publication type: Paper in international publication
Authors: Nunez-Manchon, Judit, Almendrote, Miriam, Lucente, Giuseppe, Arbex, Andrea, Puente, Carles, Lucia, Alejandro, Monckton, Darren G, Cumming, Sarah A, Pintos-Morell, Guillem, Coll-Canti, Jaume et al.
DOI: 10.3390/genes11111321

Leucocytoclastic vasculitis in a patient with COVID-19 with positive SARS-CoV-2 PCR in skin biopsy.

PMID: 33122236
Journal: BMJ case reports
Year: 2020
Reference: BMJ Case Rep. 2020 Oct 29;13(10). pii: 13/10/e238039. doi: 10.1136/bcr-2020-238039.
Impact factor: 0
Publication type: Paper in international publication
Authors: Camprodon Gomez, Maria, Gonzalez-Cruz, Carlos, Ferrer, Berta, Barbera, Maria Jesus et al.
DOI: 10.1136/bcr-2020-238039

Three-dimensional imaging in myotonic dystrophy type 1: Linking molecular alterations with disease phenotype.

PMID: 32802949
Journal: Neurology-Genetics
Year: 2020
Reference: Neurol Genet. 2020 Jul 21;6(4):e484. doi: 10.1212/NXG.0000000000000484. eCollection 2020 Aug.
Impact factor: 3.509
Publication type: Paper in international publication
Authors: Ballester-Lopez, Alfonsina, Nunez-Manchon, Judit, Koehorst, Emma, Linares-Pardo, Ian, Almendrote, Miriam, Lucente, Giuseppe, Guanyabens, Nicolau, Lopez-Osias, Marta, Suarez-Mesa, Adrian, Hanick, Shaliza Ann et al.
DOI: 10.1212/NXG.0000000000000484

Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis.

PMID: 31749608
Journal: Drug Design Development and Therapy
Year: 2019
Reference: Drug Des Devel Ther. 2019 Oct 25;13:3705-3715. doi: 10.2147/DDDT.S207856. eCollection 2019.
Impact factor: 3.208
Publication type: Paper in international publication
Authors: Beck, Michael, Hughes, Derralynn, Kampmann, Christoph, Botha, Jaco, Pintos-Morell, Guillem, West, Michael L, Niu, Dau-Ming, Nicholls, Kathy, Giugliani, Roberto, Ramaswami, Uma et al.
DOI: 10.2147/DDDT.S207856

Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain.

PMID: 31574857
Journal: MEDICINE
Year: 2019
Reference: Medicine (Baltimore). 2019 Sep;98(39):e17303. doi: 10.1097/MD.0000000000017303.
Impact factor: 1.87
Publication type: Paper in international publication
Authors: Couce, Maria Luz, Sanchez-Pintos, Paula, Aldamiz-Echevarria, Luis, Vitoria, Isidro, Navas, Victor, Martin-Hernandez, Elena, Garcia-Volpe, Camila, Pintos, Guillem, Pena-Quintana, Luis, Hernandez, Tomas et al.
DOI: 10.1097/MD.0000000000017303

Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies.

PMID: 31559131
Journal: Advanced Science
Year: 2019
Reference: Adv Sci (Weinh). 2019 Jul 24;6(18):1900849. doi: 10.1002/advs.201900849. eCollection 2019 Sep 18.
Impact factor: 15.804
Publication type: Paper in international publication
Authors: Sanchez-Garcia, Laura, Pesarrodona, Mireia, Jauset, Toni, Diaz-Riascos, Zamira V, Sanchez-Chardi, Alejandro, Beaulieu, Marie-Eve, Seras-Franzoso, Joaquin, Fernandez, Yolanda, Rinas, Ursula, Schwartz, Simo Jr et al.
DOI: 10.1002/advs.201900849

Quantification of urinary derivatives of Phenylbutyric and Benzoic acids by LC-MS/MS as treatment compliance biomarkers in Urea Cycle disorders.

PMID: 31394303
Journal: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Year: 2019
Reference: J Pharm Biomed Anal. 2019 Nov 30;176:112798. doi: 10.1016/j.jpba.2019.112798. Epub 2019 Aug 1.
Impact factor: 2.983
Publication type: Paper in international publication
Authors: Ruiz-Pons, Monica, Canedo, Elvira, Barba Romero, Miguel Angel, Garcia-Jimenez, M feminine Concepcion, Aldamiz-Echevarria, Luis, Del Toro, Mireia, Gil, David, Blasco, Javier, Andrade, Fernando, Vitoria, Isidro et al.
DOI: 10.1016/j.jpba.2019.112798

Rational Design of a siRNA Delivery System: ALOX5 and Cancer Stem Cells as Therapeutic Targets

PMID: NOMPID400
Journal:
Year: 2018
Reference: Prec. Nanomed. 2018 July;1(2):86-105
Impact factor: 0
Publication type: Paper in international publication
Authors: Martínez, Francesc, Arango, Diego et al.
DOI: 10.29016/180629.1

TNFAIP3 haploinsufficiency is the cause of autoinflammatory manifestations in a patient with a deletion of 13Mb on chromosome 6.

PMID: 29572183
Journal: CLINICAL IMMUNOLOGY
Year: 2018
Reference: Clin Immunol. 2018 Jun;191:44-51. doi: 10.1016/j.clim.2018.03.009. Epub 2018 Mar 20.
Impact factor: 3.557
Publication type: Paper in international publication
Authors: Soler-Palacin, Pere, Colobran, Roger, Aksentijevich, Ivona, Garcia-Latorre, Laura, Franco-Jarava, Clara, Wang, Hongying, Martin-Nalda, Andrea, Alvarez, de la Sierra Daniel, Garcia-Prat, Marina, Bodet, Domingo et al.
DOI: 10.1016/j.clim.2018.03.009

Dynamism, Sensitivity, and Consequences of Mesenchymal and Stem-Like Phenotype of Cancer Cells.

PMID: 30405720
Journal: Stem Cells International
Year: 2018
Reference: Stem Cells Int. 2018 Oct 10;2018:4516454. doi: 10.1155/2018/4516454. eCollection 2018.
Impact factor: 3.989
Publication type: Review in national publication
Authors: Gener, Petra, Seras-Franzoso, Joaquin, Callejo, Patricia Gonzalez, Andrade, Fernanda, Rafael, Diana, Martinez, Francesc, Montero, Sara, Arango, Diego, Sayos, Joan, Abasolo, Ibane et al.
DOI: 10.1155/2018/4516454

Changes in patellar height due to bone-tendon-bone graft.

PMID: 30173729
Journal: Revista espanola de cirugia ortopedica y traumatol
Year: 2018
Reference: Rev Esp Cir Ortop Traumatol. 2018 Sep - Oct;62(5):337-342. doi: 10.1016/j.recot.2018.03.002. Epub 2018 Jul 4.
Impact factor: 0
Publication type: Paper in national publication
Authors: Seijas, R, Sallent, A, Pons, A, Cusco, X, Catala, J, Cugat, R, Ares, O et al.
DOI: 10.1016/j.recot.2018.03.002

TNFalpha-senescence initiates a STAT-dependent positive feedback loop, leading to a sustained interferon signature, DNA damage, and cytokine secretion.

PMID: 29176033
Journal: Aging-US
Year: 2017
Reference: Aging (Albany NY). 2017 Nov 22;9(11):2411-2435. doi: 10.18632/aging.101328.
Impact factor: 4.867
Publication type: Paper in international publication
Authors: Kandhaya-Pillai, Renuka, Miro-Mur, Francesc, Alijotas-Reig, Jaume, Tchkonia, Tamara, Kirkland, James L, Schwartz, Simo et al.
DOI: 10.18632/aging.101328

Effect of Specific Mutations in Cd300 Complexes Formation; Potential Implication of Cd300f in Multiple Sclerosis.

PMID: 29051512
Journal: Scientific Reports
Year: 2017
Reference: Sci Rep. 2017 Oct 19;7(1):13544. doi: 10.1038/s41598-017-12881-8.
Impact factor: 4.259
Publication type: Paper in international publication
Authors: Martinez-Barriocanal, Agueda, Arcas-Garcia, Andrea, Magallon-Lorenz, Miriam, Ejarque-Ortiz, Aroa, Negro-Demontel, Maria Luciana, Comas-Casellas, Emma, Schwartz, Simo Jr, Malhotra, Sunny, Montalban, Xavier, Peluffo, Hugo et al.
DOI: 10.1038/s41598-017-12881-8

Loss of the EPH receptor B6 contributes to colorectal cancer metastasis.

PMID: 28262839
Journal: Scientific Reports
Year: 2017
Reference: Sci Rep. 2017 Mar 6;7:43702. doi: 10.1038/srep43702.
Impact factor: 4.259
Publication type: Paper in international publication
Authors: Mateo-Lozano, Silvia, Bazzocco, Sarah, Rodrigues, Paulo, Mazzolini, Rocco, Andretta, Elena, Dopeso, Higinio, Fernandez, Yolanda, Del Llano, Edgar, Bilic, Josipa, Suarez-Lopez, Lucia et al.
DOI: 10.1038/srep43702

Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer.

PMID: 28169277
Journal: Scientific Reports
Year: 2017
Reference: Sci Rep. 2017 Feb 7;7:41576. doi: 10.1038/srep41576.
Impact factor: 4.259
Publication type: Paper in international publication
Authors: Andretta, Elena, Carton-Garcia, Fernando, Martinez-Barriocanal, Agueda, de Marcondes, Priscila Guimaraes, Jimenez-Flores, Lizbeth M, Macaya, Irati, Bazzocco, Sarah, Bilic, Josipa, Rodrigues, Paulo, Nieto, Rocio et al.
DOI: 10.1038/srep41576

Design of chalcogen-containing norepinephrines: efficient GPx mimics and strong cytotoxic agents against HeLa cells.

PMID: 27845568
Journal: Future Medicinal Chemistry
Year: 2016
Reference: Future Med Chem. 2016 Dec;8(18):2185-2195. doi: 10.4155/fmc-2016-0139. Epub 2016 Nov 15.
Impact factor: 3.345
Publication type: Paper in international publication
Authors: Marset, Azucena, Begines, Paloma, Lopez, Oscar, Maya, Ines, Garcia-Aranda, Natalia, Schwartz, Simo Jr, Abasolo, Ibane, Fernandez-Bolanos, Jose G et al.
DOI: 10.4155/fmc-2016-0139

Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs.

PMID: 27775083
Journal: Scientific Reports
Year: 2016
Reference: Sci Rep. 2016 Oct 24;6:35765. doi: 10.1038/srep35765.
Impact factor: 5.228
Publication type: Paper in international publication
Authors: Vazquez, Esther, Schwartz, Simo, Abasolo, Ibane, Corchero, Jose Luis, Mangues, Ramon, Villaverde, Antonio, Ferrer-Miralles, Neus, Toledo-Rubio, Veronica, Sanchez-Chardi, Alejando, Cespedes, Maria Virtudes et al.
DOI: 10.1038/srep35765

Highly versatile polyelectrolyte complexes for improving the enzyme replacement therapy of lysosomal storage disorders.

PMID: 27610822
Journal: ACS Applied Materials & Interfaces
Year: 2016
Reference: ACS Appl Mater Interfaces. 2016 Oct 5;8(39):25741-25752. doi: 10.1021/acsami.6b08356. Epub 2016 Sep 22.
Impact factor: 7.145
Publication type: Paper in international publication
Authors: Abasolo, Ibane, Oliva, Mireia, Andrade, Fernanda, Garcia-Aranda, Natalia, Melgarejo, Marta, Pulido, Daniel, Corchero, Jose Luis, Fernandez, Yolanda, Villaverde, Antonio, Royo, Miriam et al.
DOI: 10.1021/acsami.6b08356

Conformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria.

PMID: 27078873
Journal: Biofabrication
Year: 2016
Reference: Biofabrication. 2016 Apr 14;8(2):025001. doi: 10.1088/1758-5090/8/2/025001.
Impact factor: 4.702
Publication type: Paper in international publication
Authors: Pesarrodona, Mireia, Fernandez, Yolanda, Foradada, Laia, Sanchez-Chardi, Alejandro, Conchillo-Sole, Oscar, Unzueta, Ugutz, Xu, Zhikun, Roldan, Monica, Villegas, Sandra, Schwartz, Simo et al.
DOI: 10.1088/1758-5090/8/2/025001

Multifunctionalized polyurethane–polyurea nanoparticles: hydrophobically driven selfstratification at the o/w interface modulates encapsulation stability†

PMID: 0002nopmid
Journal: Journal of Materials Chemistry C
Year: 2015
Reference: J. Mater. Chem. B, 2015,3, 7604-7613
Impact factor: 4.696
Publication type: Paper in international publication
Authors: Fernández Amurgo, Yolanda, Schwartz Navarro, Simon, Abasolo Olaortua, Ibane, Rocas, Pau, Albericio, Fernando et al.
DOI: 10.1039/c5tb01345c

Bioluminescent Imaging of Animal Models for Human Colorectal Cancer Tumor Growth and Metastatic Dissemination to Clinically Significant Sites

PMID: 0001nopmid
Journal: International Journal of Biochemistry and Molecular Imaging
Year: 2015
Reference: J Mol Biol & Mol Imaging. 2015;2(2): 1019
Impact factor: 0
Publication type: Paper in international publication
Authors: Fernández Amurgo, Yolanda, Foradada Felip, Laia, Garcia Aranda, Natalia, Mancilla Zamora, Sandra, Suarez Lopez, Lucia, , Herance Camacho, José Raul, Arango Corro, Diego, , Schwartz Navarro, Simon et al.
DOI:

Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells.

PMID: 26238079
Journal: Nanomedicine
Year: 2015
Reference: Nanomedicine. 2015 Nov;11(8):1883-92. doi: 10.1016/j.nano.2015.07.009. Epub 2015 Jul 31.
Impact factor: 6.155
Publication type: Paper in international publication
Authors: Arango, Diego, Gener, Petra, Gouveia, Luis Pleno, Sabat, Guillem Romero, de Sousa Rafael, Diana Fernandes, Fort, Nuria Bergada, Arranja, Alexandra, Fernandez, Yolanda, Prieto, Rafael Minana, Ortega, Joan Sayos et al.
DOI: 10.1016/j.nano.2015.07.009

Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories: production of human alpha-galactosidase A.

PMID: 25616525
Journal: APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
Year: 2015
Reference: Appl Microbiol Biotechnol. 2015 Jul;99(14):5863-74. doi: 10.1007/s00253-014-6328-9. Epub 2015 Jan 24.
Impact factor: 3.337
Publication type: Paper in international publication
Authors: Toledo-Rubio, Veronica, Unzueta, Ugutz, Vazquez, Felicitas, Accardi, Giulia, Mendoza, Rosa, Parrilli, Ermenegilda, Abasolo, Ibane, Schwartz, Simo Jr, Tutino, Maria L, Villaverde, Antonio et al.
DOI: 10.1007/s00253-014-6328-9

Ex vivo assessment of polyol coated-iron oxide nanoparticles for MRI diagnosis applications: toxicological and MRI contrast enhancement effects

PMID: 90010002
Journal: J NANOPART RES
Year: 2014
Reference: Journal of Nanoparticle Research, 2014, 16(3): 2292
Impact factor: 2.278
Publication type: Paper in international publication
Authors: Bomati-Miguel Oscar, Miguel-Sancho N , Abasolo I, Candiota AP, Roca AG, Acosta M, Schwartz Jr S, Arus C, Marquina C, Martinez G et al.
DOI:

Intracellular targeting of CD44+ cells with self-assembling, protein only nanoparticles.

PMID: 25019161
Journal: INT J PHARMACEUT
Year: 2014
Reference: Int J Pharm. 2014 Oct 1;473(1-2):286-95. doi: 10.1016/j.ijpharm.2014.07.016. Epub 2014 Jul 11.
Impact factor: 3.785
Publication type: Paper in international publication
Authors: Vazquez, Esther, Schwartz, Simo Jr, Pesarrodona, Mireia, Ferrer-Miralles, Neus, Unzueta, Ugutz, Gener, Petra, Tatkiewicz, Witold, Abasolo, Ibane, Ratera, Imma, Veciana, Jaume et al.
DOI: 10.1016/j.ijpharm.2014.07.016

SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations.

PMID: 25331979
Journal: MOL CANCER
Year: 2014
Reference: Mol Cancer. 2014 Oct 21;13:237. doi: 10.1186/1476-4598-13-237.
Impact factor: 5.397
Publication type: Paper in international publication
Authors: Meca-Cortes, Oscar, Celia-Terrassa, Toni, Fernandez, Yolanda, Abasolo, Ibane, Sanchez-Cid, Lourdes, Bermudo, Raquel, Sagasta, Amaia, Rodriguez-Carunchio, Leonardo, Pons, Monica, Canovas, Veronica et al.
DOI: 10.1186/1476-4598-13-237

Prostate tumor OVerexpressed-1 (PTOV1) down-regulates HES1 and HEY1 notch targets genes and promotes prostate cancer progression.

PMID: 24684754
Journal: MOL CANCER
Year: 2014
Reference: Mol Cancer. 2014 Mar 31;13:74. doi: 10.1186/1476-4598-13-74.
Impact factor: 5.397
Publication type: Paper in international publication
Authors: Alana, Lide, Sese, Marta, Canovas, Veronica, Punyal, Yolanda, Fernandez, Yolanda, Abasolo, Ibane, de Torres, Ines, Ruiz, Cristina, Espinosa, Lluis, Bigas, Anna et al.
DOI: 10.1186/1476-4598-13-74

Optimization of [(11)C]raclopride positron emission tomographic rat studies: comparison of methods for image quantification.

PMID: 23651503
Journal: Molecular Imaging
Year: 2013
Reference: Mol Imaging. 2013 Jun;12(4):257-62.
Impact factor: 3.408
Publication type: Paper in international publication
Authors: Pareto, Deborah, Ruiz, Alba, Gispert, Juan Domingo, Millan, Olga, Torrent, Elia, Farre, Magi, Abasolo, Ibane, Llop, Jordi et al.
DOI:

Semisynthesis, cytotoxic activity, and oral availability of new lipophilic 9-substituted camptothecin derivatives.

PMID: 24900725
Journal: ACS Medicinal Chemistry Letters
Year: 2013
Reference: ACS Med Chem Lett. 2013 May 28;4(7):651-5. doi: 10.1021/ml400125z. eCollection 2013 Jul 11.
Impact factor: 3.311
Publication type: Paper in international publication
Authors: Rodriguez-Berna, Guillermo, Cabanas, Maria Jose Diaz, Mangas-Sanjuan, Victor, Gonzalez-Alvarez, Marta, Gonzalez-Alvarez, Isabel, Abasolo, Ibane, Schwartz, Simo Jr, Bermejo, Marival, Corma, Avelino et al.
DOI: 10.1021/ml400125z

Multifunctional Nanovesicle-Bioactive Conjugates Prepared by a One-Step Scalable Method Using CO2-Expanded Solvents.

PMID: 23829208
Journal: NANO LETTERS
Year: 2013
Reference: Nano Lett. 2013 Aug 14;13(8):3766-74. doi: 10.1021/nl4017072. Epub 2013 Jul 15.
Impact factor: 13.025
Publication type: Letter whit IF
Authors: Moreno, Evelyn, Unzueta, Ugutz, Vazquez, Esther, Abasolo, Ibane, Schwartz, Simo Jr, Villaverde, Antonio, Albericio, Fernando, Royo, Miriam, Garcia-Parajo, Maria F, Ventosa, Nora et al.
DOI: 10.1021/nl4017072

Efficient intracellular delivery of siRNA with a safe multitargeted lipid-based nanoplatform.

PMID: 23394132
Journal: Nanomedicine
Year: 2013
Reference: Nanomedicine (Lond). 2013 Sep;8(9):1397-413. doi: 10.2217/nnm.12.174. Epub 2013 Feb 8.
Impact factor: 5.26
Publication type: Paper in international publication
Authors: Gomes-da-Silva, Ligia C, Fernandez, Yolanda, Abasolo, Ibane, Schwartz, Simo, Ramalho, Jose S, Pedroso de Lima, Maria C, Simoes, Sergio, Moreira, Joao N et al.
DOI: 10.2217/nnm.12.174

Human SMC2 protein, a core subunit of human condensin complex, is a novel transcriptional target of the WNT signaling pathway and a new therapeutic target

PMID: 23095742
Journal: JOURNAL OF BIOLOGICAL CHEMISTRY
Year: 2012
Reference: J Biol Chem. 2012 Dec 21;287(52):43472-81. doi: 10.1074/jbc.M112.428466. Epub 2012 Oct 24.
Impact factor: 4.773
Publication type: Paper in international publication
Authors: Davalos, Veronica, Suarez-Lopez, Lucia, Castano, Julio, Messent, Anthea, Abasolo, Ibane, Fernandez, Yolanda, Guerra-Moreno, Angel, Espin, Eloy, Armengol, Manel, Musulen, Eva et al.
DOI: 10.1074/jbc.M112.428466

Overexpression of the immunoreceptor CD300f has a neuroprotective role in a model of acute brain injury.

PMID: 21951326
Journal: BRAIN PATHOLOGY
Year: 2012
Reference: Brain Pathol. 2012 May;22(3):318-328. doi: 10.1111/j.1750-3639.2011.00537.x. Epub 2011 Oct 31.
Impact factor: 3.995
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1111/j.1750-3639.2011.00537.x

Brush border Myosin Ia has tumor suppressor activity in the intestine.

PMID: 22307608
Journal: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Year: 2012
Reference: Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1530-5. Epub 2012 Jan 18.
Impact factor: 9.681
Publication type: Paper in international publication
Authors: Arango, Diego, Mazzolini, Rocco, Dopeso, Higinio, Mateo-Lozano, Silvia, Chang, Wakam, Rodrigues, Paulo, Bazzocco, Sarah, Alazzouzi, Hafid, Landolfi, Stefania, Hernandez-Losa, Javier et al.
DOI: 10.1073/pnas.1108411109

Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation.

PMID: 21756949
Journal: JOURNAL OF CONTROLLED RELEASE
Year: 2011
Reference: J Control Release. 2011 Dec 10;156(2):246-57. Epub 2011 Jul 4.
Impact factor: 7.164
Publication type: Paper in international publication
Authors: , , , , , , , , et al.
DOI: 10.1016/j.jconrel.2011.06.039

CD300 heterocomplexes, a new and family-restricted mechanism for myeloid cell signaling regulation.

PMID: 20959446
Journal: JOURNAL OF BIOLOGICAL CHEMISTRY
Year: 2010
Reference: J Biol Chem. 2010 Dec 31;285(53):41781-94. Epub 2010 Oct 19.
Impact factor: 5.328
Publication type: Paper in international publication
Authors: , , , , et al.
DOI: 10.1074/jbc.M110.140889

Depressed glucose consumption at reperfusion following brain ischemia does not correlate with mitochondrial dysfunction and development of infarction: an in vivo positron emission tomography study.

PMID: 19442156
Journal: CURRENT NEUROVASCULAR RESEARCH
Year: 2009
Reference: Curr Neurovasc Res. 2009 May;6(2):82-8.
Impact factor: 3.571
Publication type: Paper in international publication
Authors: Martin, Abraham, Rojas, Santiago, Pareto, Deborah, Santalucia, Tomas, Millan, Olga, Llop, Jordi, Gispert, Joan D, Falcon, Carles, Bargallo, Nuria, Planas, Anna M et al.
DOI:

FDG PET imaging of Ela1-myc mice reveals major biological differences between pancreatic acinar and ductal tumours.

PMID: 19252908
Journal: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Year: 2009
Reference: Eur J Nucl Med Mol Imaging. 2009 Jul;36(7):1156-66.
Impact factor: 4.532
Publication type: Paper in international publication
Authors: Abasolo, Ibane, Pujal, Judit, Rabanal, Rosa M, Serafin, Anna, Navarro, Pilar, Millan, Olga, Real, Francisco X et al.
DOI: 10.1007/s00259-009-1083-3

Keratin 7 promoter selectively targets transgene expression to normal and neoplastic pancreatic ductal cells in vitro and in vivo.

PMID: 19124560
Journal: FASEB JOURNAL
Year: 2009
Reference: FASEB J. 2009 May;23(5):1366-75.
Impact factor: 7.049
Publication type: Paper in international publication
Authors: Pujal, Judit, Huch, Meritxell, Jose, Anabel, Abasolo, Ibane, Rodolosse, Annie, Duch, Alba, Sanchez-Palazon, Luis, Smith, Frances J D, McLean, W H Irwin, Fillat, Cristina et al.
DOI: 10.1096/fj.08-115576

Thesis

Design, synthesis and biological evaluation of new polymer-drug conjugates based on polyglutamic acid and 5-fluorouracil for the treatment of advanced colorectal cancer

PhD student: Helena Plà Solans
Director/s: Simon Schwartz Navarro, Ibane Abasolo Olaortua
University: Universitat Autònoma de Barcelona
Year: 2014

Caracterización de la amplificación y sobreexpresión génica del proto-oncogen C-ERBB2 (Neu),del receptor del factor de crecimiento epidérmico y del factor de crecimiento fibroblástico 3-INT2, en el adenocarcinoma prostático y en la hiperplasia benigna de próstata.

PhD student: Simon Schwartz Navarro
Director/s: Jaume Reventós Puigjaner
University: Universitat Autònoma de Barcelona
Year: 1996

Blog

News

Durant el mes de juny, organitzem tres activitats sobre assaigs clínics, genètica i imatges científiques.

The AECC Research Grants for 2021 will drive the research headed by Dr Fernanda da Silva and Dr Eva Colás.

VHIR collaborates with Nanbiosis through the FVPR service platform created within the Drug Delivery and Targeting Research Group (DTT).

Job offers

Graduate Technician - Drug Delivery & Targeting (DDT)
Start date:
25/07/2022
End date:
08/08/2022
Document: Download
Junior Project Manager. DDT - ARO
Start date:
05/07/2022
End date:
19/07/2022
Document: Download
Laboratory Technician, for histological processing Técnico de anatomía patológica (AP).
Start date:
22/06/2022
End date:
30/06/2022
Document: Download